EUVIMEDEUVIMED entdecken
Crossref

Dupilumab (Dupixent) for Eosinophilic Esophagitis and Prurigo Nodularis

The Medical Letter on Drugs and Therapeutics · 2023

DOI: 10.58347/tml.2023.1669b ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Prurigo, Eosinophilic Esophagitis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FDA has approved the subcutaneously injected interleukin (IL)-4 receptor alpha antagonist dupilumab (Dupixent – Sanofi/Regeneron) for treatment of eosinophilic esophagitis (EoE) in patients ≥12 years old who weigh ≥40 kg and treatment of prurigo nodularis in adults.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PrurigoEosinophilic EsophagitisGastritisHumansImmunosuppressive AgentsEosinophiliaAntibodies, Monoclonal, HumanizedEnteritis

Stichwörter der Autor:innen

Dupixentadverse effectsantidepressantsazathioprinecyclosporinedosagedrug interactionsdupilumabefficacyeosinophilic esophagitislactationlenalidomidemethotrexatephototherapypregnancy

Substanzen

dupilumabImmunosuppressive AgentsAntibodies, Monoclonal, Humanized

Zitieren

APA

(2023). Dupilumab (Dupixent) for Eosinophilic Esophagitis and Prurigo Nodularis. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1669b

Vancouver

Dupilumab (Dupixent) for Eosinophilic Esophagitis and Prurigo Nodularis. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1669b

BibTeX
@article{euvimed2023,
  title = {Dupilumab (Dupixent) for Eosinophilic Esophagitis and Prurigo Nodularis},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2023},
  doi = {10.58347/tml.2023.1669b}
}
Kostenlos starten →